Mirabegron 5 mg (Extended Release) + Solifenacin Succinate IP 5 mg is a dual-action therapy used in the management of Overactive Bladder (OAB). This advanced combination works through two complementary mechanisms to improve bladder control and reduce urinary urgency, frequency, and urge incontinence. Mirabegron is a selective beta-3 adrenergic receptor agonist that relaxes the bladder detrusor muscle during the storage phase, increasing bladder capacity without affecting normal voiding. Solifenacin is an antimuscarinic agent that reduces involuntary bladder contractions by blocking muscarinic receptors in the bladder. Together, this combination provides superior symptom control compared to monotherapy in patients who need additional relief from OAB symptoms. It is especially beneficial for adults experiencing: Frequent urination Sudden urge to urinate Urge urinary incontinence Nocturia (night-time urination)
